March 29, 1994 - March 29, 2027

  • Date:29MondayMay 2017

    Combination therapies and drug resistance in Triple Negative Breast Cancer

    More information
    Time
    14:00 - 15:00
    Title
    Cancer Research Club
    Location
    Max and Lillian Candiotty Building
    Seminar Room
    Lecturer
    Prof. Sima Lev
    Department of Molecular Cell Biology, Weizmann Institute
    Organizer
    Department of Immunology and Regenerative Biology
    Contact
    AbstractShow full text abstract about Triple negative breast cancer (TNBC) is a highly aggressive,...»
    Triple negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with high rates of metastasis and poor prognosis. Currently, there are no targeted therapies for TNBC and adjuvant chemotherapy is the mainstay treatment. Identification of molecular targets and potent combination therapies for TNBC is a major challenge of extensive biomedical research and our own studies. Given that drug resistance is a critical clinical problem, a drug combination that could overcome drug resistance could offer a promising therapeutic opportunity. We have recently identified potent combination therapies for TNBC which are not only potent but could also overcome drug resistance and further defined the molecular mechanisms underlying their therapeutic benefit.
    Lecture